Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine.

• Autores: Shannon Stokley, Kate M Shaw, Lawrence Barker, Jeanne M Santoli, Abigail Shefer
• Localización: American journal of public health, ISSN 0090-0036, Vol. 96, Nº. 7, 2006, págs. 1308-1313
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: We examined heptavalent pneumococcal conjugate vaccine (PCV7) uptake among children aged 19 to 35 months in the United States and determined how uptake rates differed by state vaccine financing policy.; Methods: We analyzed data from the 2001-2003 National Immunization Survey. States that changed their vaccine financing policy between 2001 and 2003 (n=17) were excluded from analysis. Logistic regression was performed to identify the association between state vaccine financing policy and receipt of 3 or more doses of PCV7 after control for demographic characteristics.; Results: The proportion of children receiving 3 or more doses increased from 6.7% in 2001 to 69.0% in 2003. After controlling for demographic characteristics, children residing in states that provided all vaccines except PCV7 to all children had lower odds of receiving 3 or more doses compared to children residing in states that provided PCV7 only to children eligible for the Vaccines for Children program (odds ratio=0.58; 95% confidence interval=0.51, 0.66).; Conclusion: It is essential that we continue to monitor the effect that state vaccine financing policy has on the delivery of PCV7 and future vaccines, which are likely to be increasingly expensive.;